Psychosocial outcomes after initial treatment of erectile dysfunction with tadalafil once daily, tadalafil on demand or sildenafil citrate on demand: Results from a randomized, open-label study

International Journal of Impotence Research

Volumn 26, Issue 6, 2014, Pages 223-229

  Hatzimouratidis, K ^a   Buvat, J ^b   Buttner H ^c   Vendeira, P A S ^d   Moncada, I ^e   Boehmer, M ^f   Henneges, C ^c   Boess, F G ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b Centre Etude et de Traitement de la Pathologie de l'Appareil   (France)

^c LILLY DEUTSCHLAND GMBH   (Germany)

^d Clínica Saúde Atlântica Estádio do Dragão   (Portugal)

^e HOSPITAL LA ZARZUELA   (Spain)

^f Diabetological Practice   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

SILDENAFIL; TADALAFIL; CARBOLINE DERIVATIVE; PHOSPHODIESTERASE INHIBITOR; PIPERAZINE DERIVATIVE; PURINE DERIVATIVE; SULFONAMIDE;

ADULT; ARTICLE; DRUG INDUCED HEADACHE; ED INVENTORY OF TREATMENT SATISFACTION; ERECTILE DYSFUNCTION; GLOBAL ASSESSMENT QUESTION; HUMAN; INTERNATIONAL INDEX OF ERECTILE FUNCTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; OPEN STUDY; PARALLEL DESIGN; PATIENT COMPLIANCE; PSYCHOLOGICAL AND INTERPERSONAL RELATIONSHIP SCALE; SELF ESTEEM AND RELATIONSHIP QUESTIONNAIRE; SEXUAL ENCOUNTER PROFILE; SOCIAL PSYCHOLOGY; TREATMENT DURATION; TREATMENT OUTCOME; AGED; CLINICAL TRIAL; CONTROLLED STUDY; MIDDLE AGED; PATIENT SATISFACTION; PENIS ERECTION; PSYCHOLOGY; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SELF CONCEPT; SEVERITY OF ILLNESS INDEX;

AGED; CARBOLINES; ERECTILE DYSFUNCTION; HUMANS; MALE; MIDDLE AGED; PATIENT SATISFACTION; PENILE ERECTION; PHOSPHODIESTERASE INHIBITORS; PIPERAZINES; PURINES; QUESTIONNAIRES; SELF CONCEPT; SEVERITY OF ILLNESS INDEX; SULFONAMIDES; TREATMENT OUTCOME;

EID: 84909949278     PISSN: 09559930     EISSN: 14765489     Source Type: Journal    
DOI: 10.1038/ijir.2014.15     Document Type: Article

References (26)

1. Goldstein I, Lue TF, Padma-Nathan H, Rosen RC, Steers WD, Wicker PA. Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group. N Engl J Med 1998; 338: 1397-1404.
2. Brock GB, McMahon CG, Chen KK, Costigan T, Shen W, Watkins V et al. Efficacy and safety of tadalafil for the treatment of erectile dysfunction: results of integrated analyses. J Urol 2002; 168: 1332-1336.
3. Hellstrom WJ, Gittelman M, Karlin G, Segerson T, Thibonnier M, Taylor T et al. Vardenafil for treatment of men with erectile dysfunction: efficacy and safety in a randomized, double-blind, placebo-controlled trial. J Androl 2002; 23: 763-771.
4. Porst H, Rajfer J, Casabé A, Feldman R, Ralph D, Vieiralves LF et al. Long-term safety and efficacy of tadalafil 5mg dosed once daily in men with erectile dysfunction. J Sex Med 2008; 5: 2160-2169.
5. Montorsi F, Aversa A, Moncada I, Perimenis P, Porst H, Barker C et al. A randomized, double-blind, placebo-controlled, parallel study to assess the efficacy and safety of once-a-day tadalafil in men with erectile dysfunction who are naïve to PDE5 inhibitors. J Sex Med 2011; 8: 2617-2624.
6. Tsertsvadze A, Fink HA, Yazdi F, MacDonald R, Bella AJ, Ansari MT et al. Oral phosphodiesterase-5 inhibitors and hormonal treatments for erectile dysfunction: a systematic review and meta-analysis. Ann Intern Med 2009; 151: 650-661.
7. Rosen RC, Fisher WA, Eardley I, Niederberger C, Nadel A, Sand M. The multinational Men's Attitudes to Life Events and Sexuality (MALES) study: I. Prevalence of erectile dysfunction and related health concerns in the general population. Curr Med Res Opin 2004; 20: 605-617.
8. Hatzichristou D, Haro J, Martin-Morales A, von Keitz A, Riley A, Bertsch J et al. Patterns of switching PDE5 inhibitors in the treatment of erectile dysfunction: results from the Erectile Dysfunction Observational Study. Int J Clin Pract 2007; 61: 1850-1862.
9. Buvat J, Büttner H, Hatzimouratidis K, Vendeira P, Moncada I, Boehmer M et al. Adherence to initial PDE5 inhibitor treatment: randomized open-label study comparing tadalafil once a day, tadalafil on demand and sildenafil on demand in patients with erectile dysfunction. J Sex Med 2013; 10: 1592-1602.
10. Walker DK, Ackland MJ, James GC, Muirhead GJ, Rance DJ, Wastall P et al. Pharmacokinetics and metabolism of sildenafil in mouse, rat, rabbit, dog and man. Xenobiotica 1999; 29: 297-310.
11. Forgue ST, Patterson BE, Bedding AW, Payne CD, Phillips DL, Wrishko RE et al. Tadalafil pharmacokinetics in healthy subjects. Br J Clin Pharmacol 2006; 61: 280-288.
12. Porst H, Padma-Nathan H, Giuliano F, Anglin G, Varanese L, Rosen R. Efficacy of tadalafil for the treatment of erectile dysfunction at 24 and 36 hours after dosing: a randomized controlled trial. Urology 2003; 62: 121-125.
13. Young JM, Feldman RA, Auerbach SM, Kaufman JM, Garcia CS, Shen W et al. Tadalafil improved erectile function at twenty-four and thirty-six hours after dosing in men with erectile dysfunction: US trial. J Androl 2005; 26: 310-318.
14. Gingell C, Sultana SR, Wulff MB, Gepi-Attee S. Duration of action of sildenafil citrate in men with erectile dysfunction. J Sex Med 2004; 1: 179-184.
15. Wrishko R, Sorsaburu S, Wong D, Strawbridge A, McGill J. Safety, efficacy, and pharmacokinetic overview of low-dose daily administration of tadalafil. J Sex Med 2009; 6: 2039-2048.
16. Rajfer J, Aliotta PJ, Steidle CP, Fitch 3rd WP, Zhao Y, Yu A. Tadalafil dosed once a day in men with erectile dysfunction: a randomized, double-blind, placebo-controlled study in the US. Int J Impot Res 2007; 19: 95-103.
17. Althof SE. When an erection alone is not enough: biopsychosocial obstacles to lovemaking. Int J Impot Res 2002; 14(Suppl 1): S99-S104.
18. Dean J, Hackett GI, Gentile V, Pirozzi-Farina F, Rosen RC, Zhao Y et al. Psychosocial outcomes and drug attributes affecting treatment choice in men receiving sildenafil citrate and tadalafil for the treatment of erectile dysfunction: results of a multicenter, randomized, open-label, crossover study. J Sex Med 2006; 3: 650-661.
19. Hatzimouratidis K, Amar E, Eardley I, Giuliano F, Hatzichristou D, Montorsi F et al. European Association of Urology. Guidelines on male sexual dysfunction: erectile dysfunction and premature ejaculation. Eur Urol 2010; 57: 804-814.
20. Swindle RW, Cameron AE, Lockhart DC, Rosen RC. The psychological and interpersonal relationship scales: assessing psychological and relationship outcomes associated with erectile dysfunction and its treatment. Arch Sex Behav 2004; 33: 19-30.
21. Cappelleri JC, Althof SE, Siegel RL, Shpilsky A, Bell SS, Duttagupta S. Development and validation of the Self-Esteem And Relationship (SEAR) questionnaire in erectile dysfunction. Int J Impot Res 2004; 16: 30-38.
22. Rosen RC, Riley A, Wagner G, Osterloh IH, Kirkpatrick J, Mishra A. The international index of erectile function (IIEF): a multidimensional scale for the assessment of erectile dysfunction. Urology 1997; 49: 822-830.
23. Cappelleri JC, Rosen RC, Smith MD, Mishra A, Osterloh IH. Diagnostic evaluation of the erectile function domain of the International Index of Erectile Function. Urology 1999; 54: 346-351.
24. Althof SE, Corty EW, Levine SB, Levine F, Burnett AL, McVary K et al. EDITS: development of questionnaires for evaluating satisfaction with treatments for erectile dysfunction. Urology 1999; 53: 793-799.
25. Rubio-Aurioles E, Porst H, Kim ED, Montorsi F, Hackett G, Morales AM et al. A randomized open-label trial with a crossover comparison of sexual self-confidence and other treatment outcomes following tadalafil once a day vs tadalafil or sildenafil on-demand in men with erectile dysfunction. J Sex Med 2012; 9: 1418-1429.
26. El Khiat Y, Ghazi S, Allam A, Khawaja M, Belger M, Tamer M et al. Psychosocial impact and effectiveness of tadalafil among treatment-naïve and previouslytreated men with erectile dysfunction in Saudi Arabia and other Gulf-region countries. Curr Med Res Opin 2008; 24: 1965-1973.